ChainzokuのLPで使われているフォントは？

HelveticaNeue-Light / NeueHaasGrotDisp-76BoldItalic / AkzidenzGrotesk-BoldExtended / DrukHeavy

ChainzokuのLPの主要カラーは？

背景不明 / テキスト #000000 / アクセント #000000

ChainzokuのLPのh1見出しのスペックは？

AkzidenzGrotesk-BoldExtended / 12px / weight 400 / line 14px / tracking -0.24px

ChainzokuのLPのセクション余白は？

主要セクション上下余白 0px / 250px / 200px

Personalis のWebデザイン | ASI Design Gallery

Q: ChainzokuのLPの主要カラーは？

背景 不明 / テキスト #000000 / アクセント #000000

Our advanced ctDNA technologies enable the most sensitive detection with cancer insights from molecular residual disease to therapy selection.

We use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic. By clicking "Accept All", you consent to our use of cookies. Customize Reject All Accept All PERSONALIS LAUNCHES REAL-TIME VARIANT TRACKER™ NATIONWIDE, EXPANDING NEXT PERSONAL® BEYOND MRD DETECTION PERSONALIS LAUNCHES REAL-TIME VARIANT TRACKER™ NATIONWIDE, EXPANDING NEXT PERSONAL® BEYOND MRD DETECTION CLINICAL PORTAL REQUEST INFO WHO WE ARE Company Team Partnerships Careers Technology On-Site Clinical Lab JOIN OUR TEAM Together, we can transform the future of cancer care. Careers FOR CLINICIANS For Clinicians NeXT Personal® Lung Cancer Breast Cancer Real-Time Variant Tracker™ NeXT Dx® For Pathologists Billing & NeXT Access CLINICAL DATA Tracking early stage breast cancer with ultrasensitive ctDNA Download FOR PATIENTS For Patients NeXT Dx® | Tumor Profiling NeXT Personal® | ctDNA Liquid Biopsy Payment Information Financial Assistance & NeXT Access Patient FAQs PATIENT BROCHURE Information for patients with breast cancer Download FOR BIOPHARMA For Biopharma NeXT Personal | MRD Liquid Biopsy ImmunoID NeXT | Biomarker Platform CLINICAL DATA Monitoring therapy response with ultrasensitive ctDNA across cancer types Download LEARN MORE All Resources News Events & Presentations Library Scientific Publications Contact PEER REVIEWED PUBLICATION Ultrasensitive ctDNA detection in early-stage lung cancer Download INVESTORS Overview Press Releases Events & Presentations Quarterly Results Stock Information Analyst Coverage SEC Filings Corporate Governance Committee Composition FAQs Email Alerts Contact IR INVESTING IN INNOVATION Personalis is transforming the development of next-generation therapies. Investors SEARCH Submit What more could MRD testing reveal? NeXT Personal® MRD Test Redefining what’s possible in MRD. When only trace amounts of ctDNA are present, the MRD test you choose matters. Learn More Now Available: Real-Time Variant Tracker™. Rea